+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027

  • PDF Icon

    Report

  • 292 Pages
  • January 2022
  • Region: Global
  • Arizton
  • ID: 5530298
UP TO OFF until Apr 01st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cell and gene therapy market size was valued at USD 4.99 billion in 2021 and is expected to reach USD 36.92 billion by 2027, growing at a CAGR of 39.62 % during the forecast period

The following factors are likely to contribute to the growth of the cell and gene therapy market:

  • Merger & Acquisition
  • Expansion of Manufacturing Plants & Technological Advancement
  • Expanding Application for Cell & Gene Therapies
  • Growing Demand for CAR T- Cell Therapies
  • New Products Approvals & Increasing Pipeline Products

In the cell and gene therapy field, gene therapy gathered the pace last from 2 decades because of the discovery of several genes responsible for mutation in various diseases. The advancement in the cell & gene therapy field and innovative technologies give the new era for biological therapeutics. Also, PRIME Designation and marketing authorization for products provide a new opportunity for the manufacturer's financing and revenue generation.

KEY HIGHLIGHTS

  • As per the American Society of Cell + Gene Therapy report in 2021, increasing the number of cellular and gene therapy products, application rate and products in clinical trials drive the market growth.
  • As per the Dive Biopharma report 2021, biotech companies who actively engaged in regenerative medicines and therapies reported USD 14 billion funding only in six months of 2021 which was reported to be USD 19.9 billion for the overall year.

CELL AND GENE THERAPY MARKET SEGMENTS


Cell and gene therapy market is segmented on the basis of:

  • Therapy type
  • Application
  • End-users
  • Geography

CELL AND GENE THERAPY MARKET SEGMENTATION

  • Increasing application of gene therapies in diseases diagnosis and rapidly growing new drugs applications will give new market space in upcoming years. In 2020, around USD 2.3 billion funding was reported only from private companies for gene therapies. By 2025, the FDA is expected to approve 10−20 products each year, driving the global cell and gene therapy manufacturing market.
  • In 2020, Medicine in Development Report 2020, around 176 products were reported in cancer therapies in development procedures.

Market segmentation by Therapy Type

  • Gene Therapy
  • Cell Therapy

Market segmentation by Application

  • Oncology
  • Genetic Disorders
  • Dermatology Disorders
  • Musculoskeletal Disorders
  • Others

Market segmentation by End-Users

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others

GEOGRAPHICAL OUTLOOK

  • North America: High economic status and high expenditure on healthcare services drive the cell and gene therapy market in North America. National Health Institutes, industries, academic institutes, and hospitals are the significant contributors of sponsorship and financial funding for cell and gene therapy products.
  • Europe: The increasing funding for cell and gene therapy drives the cell and gene therapy market growth consistently in Europe. Around USD 2.6 billion financings were reported in Europe for CGTs in 2020, which increased by 103% compared to previous years. In the cell therapy segment, USD 1.8 billion and in gene therapy, USD 2.3 billion funding accounted in 2020, which increased by 196% and 111% growth respectively

Market segmentation by Geography

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • APAC
  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel

VENDOR LANDSCAPE

  • The key players in the cell and gene therapy market are Gilead Sciences, Novartis, Smith Nephew, Amgen, Organogenesis, Roche (Spark Therapeutics), Dendreon, Vericel, and Bristol-Myers Squibb Company.
  • An increasing number of mergers and acquisitions gives new potential to market growth. Gilead Sciences acquired Kite Pharma in 2020. Also, Novartis acquired Avexis in 2018, and Smith & Nephew acquired Osiris Therapeutics.

Key Vendors

  • Gilead sciences
  • Novartis
  • Smith Nephew (Osiris Therapeutic)
  • Amgen
  • Organogenesis
  • Roche (Spark Therapeutics)
  • Dendreon
  • Vericel
  • Bristol-Myers Squibb

Other Prominent Vendors

  • Abeona Therapeutics
  • APAC Biotech Pvt Ltd
  • Alnylam
  • Allovir
  • Tego Sciences
  • Avita Medical
  • Anterogen
  • AnGes Inc.
  • BioSolution Co. Ltd.
  • Cheisi Farmaceutici
  • CollPlant
  • CO.DON
  • Corestem
  • Bluebird Bio Inc
  • Biosolution
  • Stempeutics Research
  • GC Cell
  • Sanofi
  • Gensight biologics
  • Human Stem Cells Institute
  • JW CreaGene Co. Ltd
  • JCR Pharmaceuticals
  • Japan Tissue Engineering (J-TEC)
  • Kolon TissueGene
  • Medipost
  • MolMed
  • Nuvasive Inc.
  • Nipro Corporation
  • Orchard Therapeutics
  • Orthocell
  • Pfizer
  • Pharmicell
  • Sibiono Genetech
  • Shanghai Sunway Biotech
  • RMS Regenerative Medical System
  • Takeda Pharmaceuticals Company
  • Terumo

Upcoming Vendors

  • Biomarin Pharmaceutical
  • Bellicum Pharmaceutical
  • Castle Creek Biosciences Inc
  • Libella Gene Therapeutics
  • CARsgen Therapeutics
  • Hrain Biotechnology Co. Ltd
  • Helixmith
  • Krystal Biotech Inc.
  • JW Therapeutic
  • Poseida Therapeutics

KEY QUESTIONS ANSWERED:


1. How big is the global cell & gene therapy market?
2. What are the latest trends in the cell & gene therapy market?
3. Who are the key players in the cell & gene therapy market?
4. Which region has the highest share in the cell & gene therapy market?
5. Who are the end-users of the cell & gene therapy market?

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Cell & Gene Therapy Approved Products 2020-2021
7.2 Cell & Gene Therapy Phase-III Products
7.3 Road Map of Cell & Gene Therapy
8 Market Opportunities & Trends
8.1 Rising Number of Mergers & Acquisitions
8.2 Expansion of CGT Manufacturing Plants
8.3 Expanding Applications for Cell & Gene Therapies
8.4 Growing Demand for Car T-Cell Therapies
9 Market Growth Enablers
9.1 New Product Approvals & Increasing Pipeline of Products
9.2 Prime Designation & Funding Support For CGT
9.3 Rising Use of CGT Products for Disease Care
9.4 Increasing Use of CGT Products for Disease Treatment
10 Market Restraints
10.1 High Cost of Cell & Gene Therapies
10.2 Ethical Issues Regarding Genetical Material
10.3 Stringent Regulation for CGT Approvals
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 Therapy
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Gene Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Cell Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast
13 Application
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Genetic Disorders
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Dermatology
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Musculoskeletal Diseases
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.7 Other Diseases
13.7.1 Market Overview
13.7.2 Market Size & Forecast
14 End-User
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Cancer Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Wound Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Other End-Users
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
15.2.1 Global Cell & Gene Therapy Market by Geography
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast
17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany: Market Size & Forecast
17.3.2 France: Market Size & Forecast
17.3.3 UK: Market Size & Forecast
17.3.4 Spain: Market Size & Forecast
17.3.5 Italy: Market Size & Forecast
18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan: Market Size & Forecast
18.3.2 China: Market Size & Forecast
18.3.3 South Korea: Market Size & Forecast
18.3.4 Australia: Market Size & Forecast
18.3.5 India: Market Size & Forecast
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast
20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 Saudi Arabia: Market Size & Forecast
20.3.3 UAE: Market Size & Forecast
20.3.4 South Africa: Market Size & Forecast
20.3.5 Israel: Market Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
22 Key Company Profiles
22.1 GILEAD SCIENCES
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 NOVARTIS
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 SMITH NEPHEW (OSIRIS THERAPEUTICS)
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 AMGEN
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 ORGANOGENESIS
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
22.6 ROCHE (SPARK THERAPEUTICS)
22.6.1 Business Overview
22.6.2 Product Offerings
22.6.3 Key Strategies
22.6.4 Key Strengths
22.6.5 Key Opportunities
22.7 DENDREON
22.7.1 Business Overview
22.7.2 Product Offerings
22.7.3 Key Strategies
22.7.4 Key Strengths
22.7.5 Key Opportunities
22.8 VERICEL
22.8.1 Business Overview
22.8.2 Product Offerings
22.8.3 Key Strategies
22.8.4 Key Strengths
22.8.5 Key Opportunities
22.9 BRISTOL MEYER SQUIBB
22.9.1 Business Overview
22.9.2 Product Offerings
22.9.3 Key Strategies
22.9.4 Key Strengths
22.9.5 Key Opportunities
23 Other Prominent Vendors
23.1 ABEONA THERAPEUTICS
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 APAC BIOTECH PVT LTD
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 ALNYLAM
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 ALLOVIR
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 TEGO SCIENCES
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 AVITA MEDICAL
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 ANTEROGEN
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 ANGES INC
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 BIOSOLUTION CO. LTD
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 CHEISI FARMACEUTICI
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 COLLPLANT
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 CO.DON
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 CORESTEM
23.13.1 Business Overview
23.14 BLUEBIRD BIO INC
23.14.1 Business Overview
23.14.2 Product Offerings
23.15 STEMPEUTICS RESEARCH
23.15.1 Business Overview
23.15.2 Product Offerings
23.16 Gc Cell
23.16.1 Product Offerings
23.17 SANOFI
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 GENSIGHT BIOLOGICS
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 HUMAN STEM CELL INSTITUTE
23.19.1 Business Overview
23.19.2 Product Offerings
23.20 JW CREAGENE CO. LTD
23.20.1 Business Overview
23.20.2 Products Offerings
23.21 JCR PHARMACEUTICALS
23.21.1 Business Overview
23.21.2 Products Offerings
23.22 JAPAN TISSUE ENGINEERING (J-TEC)
23.22.1 Business Overview
23.22.2 Product Offerings
23.23 KOLON TISSUEGENE
23.23.1 Business Overview
23.23.2 Product Offerings
23.24 MEDIPOST
23.24.1 Business Overview
23.24.2 Product Offerings
23.25 MOLMED
23.25.1 Business Overview
23.25.2 Product Offerings
23.26 NUVASIVE INC
23.26.1 Business Overview
23.26.2 Product Offerings
23.27 NIPRO CORPORATION
23.27.1 Business Overview
23.27.2 Product Offerings
23.28 ORCHARD THERAPEUTICS
23.28.1 Business Overview
23.28.2 Product Offerings
23.29 ORTHOCELL
23.29.1 Business Overview
23.29.2 Product Offerings
23.30 PFIZER
23.30.1 Business Overview
23.30.2 Product Offerings
23.31 PHARMICELL
23.31.1 Business Overview
23.31.2 Product Offerings
23.32 SIBIONO GENETECH
23.32.1 Business Overview
23.32.2 Product Offerings
23.33 SHANGHAI SUNWAY BIOTECH
23.33.1 Business Overview
23.33.2 Product Offerings
23.34 RMS REGENERATIVE MEDICAL SYSTEM
23.34.1 Business Overview
23.34.2 Product Offerings
23.35 TAKEDA PHARMACEUTICALS COMPANY
23.35.1 Business Overview
23.35.2 Product Offerings
23.36 TERUMO
23.36.1 Business Overview
23.36.2 Product Offerings
24 Upcoming Market Vendors
24.1 BIOMARIN PHARMACEUTICALS
24.1.1 Business Overview
24.1.2 Product Offerings
24.2 BELLICUM PHARMACEUTICALS
24.2.1 Business Overview
24.2.2 Product Offering
24.3 CASTLE CREEK BIOSCIENCES INC.
24.3.1 Business Overview
24.3.2 Product Offerings
24.4 LIBELLA GENE THERAPEUTICS
24.4.1 Business Overview
24.4.2 Product Offerings
24.5 CARSGEN THERAPEUTICS
24.5.1 Business Overview
24.5.2 Product Offerings
24.6 HRAIN BIOTECHNOLOGY CO. LTD.
24.6.1 Business Overview
24.6.2 Product Offerings
24.7 HELIXMITH
24.7.1 Business Overview
24.7.2 Product Offerings
24.8 KRYSTAL BIOTECH INC.
24.8.1 Business Overview
24.8.2 Product Offerings
24.9 JW THERAPEUTICS
24.9.1 Business Overview
24.9.2 Product Offerings
24.10 POSEIDA THERAPEUTICS
24.10.1 Business Overview
24.10.2 Product Offerings
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Market by Geography
26.1.1 Global Cell & Gene Therapy Market by Geography
26.1.2 Global Cell & Gene Therapy Market by Therapy Type
26.1.3 Global Cell & Gene Therapy Market by Diseases
26.1.4 Global Cell & Gene Therapy Market by End-User
27 Appendix
27.1 Abbreviations
LIST OF EXHIBITS
Exhibit 1 Segmentation of Global Cell & Gene Therapy Market
Exhibit 2 Market Size Calculation Approach 2021
Exhibit 3 Cell Therapy Products in Pipeline 2021
Exhibit 4 Progress in Cell & Gene Therapy Products & Development
Exhibit 5 Impact of Rising Number of Mergers & Acquisitions
Exhibit 6 Impact of Expansion of CGT Manufacturing Plants
Exhibit 7 Impact of Expanding Applications for Cell & Gene Therapies
Exhibit 8 Impact of Growing Demand for CAR T-cell Therapies
Exhibit 9 Major Vendors Engaged in Development of CAR T-Cell Therapies
Exhibit 10 Impact of New Products Approvals & Increasing Pipeline of Products
Exhibit 11 Gene Therapies in Pipeline 2020 vs 2021
Exhibit 12 Impact of Prime Designation &Funding Support for CGT
Exhibit 13 Global Regenerative Medicine Financing 2019-2021 ($ billion)
Exhibit 14 Impact of Rising Use of CGT Products for Disease Care
Exhibit 15 Cell & Gene Therapy Products in Development 2020
Exhibit 16 Hematological Cancer Diseases Treated Patients by Cell & Gene Therapy 2018-2020
Exhibit 17 Impact of Increasing Use of CGT Products for Disease Treatment
Exhibit 18 Impact of High Cost of Cell & Gene Therapies
Exhibit 19 Impact of Ethical Issues Regarding Genetical Material
Exhibit 20 Risk Factors of Cell & Gene Therapy
Exhibit 21 Impact of Stringent Regulation for CGT Approvals
Exhibit 22 Global Cell & Gene Therapy Market 2021-2027 ($ billion)
Exhibit 23 Five Forces Analysis 2021
Exhibit 24 Incremental Growth by Therapy 2021 & 2027 ($ million)
Exhibit 25 Financing for Cell & Gene Therapies 2019-2021 (H1) ($ billion)
Exhibit 26 Global Cell & Gene Therapy Market by Therapy Type: Incremental Growth
Exhibit 27 Global Cell & Gene Therapy Market by Therapy Type: Absolute Growth
Exhibit 28 Financing for Gene Therapy 2019-2021 (H1) ($ billion)
Exhibit 29 Industry-based & Academic, Government, & Other Gene Therapy Clinical Trials 2021
Exhibit 30 Global Gene Therapy Market by Gene Therapy: Incremental & Absolute Growth
Exhibit 31 Global Gene Therapy Market 2021-2027 ($ million)
Exhibit 32 Application of Cell Therapies in Diagnosis
Exhibit 33 Financing for Cell Therapies ($ billion)
Exhibit 34 Number of Cell Therapies in Pipeline 2019-2021
Exhibit 35 Global Cell Therapy Market: Incremental & Absolute Growth
Exhibit 36 Global Cell Therapy Market 2021-2027 ($ million)
Exhibit 37 Incremental Growth by Application 2021 & 2027
Exhibit 38 Global Cell & Gene Therapy Market by Diseases: Incremental Growth
Exhibit 39 Global Cell & Gene Therapy Market by Diseases: Absolute Growth
Exhibit 40 Cancer Therapy Products in Pipeline 2020 (%)
Exhibit 41 Cell & Gene Therapy Products for Cancer Treatment
Exhibit 42 Product Pipeline for Gene Therapy in Cancer (2020)
Exhibit 43 Global Cell & Gene Therapy Market by Oncology: Incremental & Absolute Growth
Exhibit 44 Global Cell & Gene Therapy Market by Oncology 2021-2027 ($ million)
Exhibit 45 Genetic Disorders & Cell & Gene Therapy Products in Development (%)
Exhibit 46 Cell & Gene Therapy Products in Clinical Trials for Genetic Disorders 2019-2021 (H1)
Exhibit 47 Product Pipeline in Cell & Gene Therapy for Treatment of Rare Diseases (2021)
Exhibit 48 Global Cell & Gene Therapy Market by Genetic Disorders: Incremental & Absolute Growth
Exhibit 49 Global Cell & Gene Therapy Market by Genetic Disorders 2021-2027 ($ million)
Exhibit 50 Number of Cell & Gene Therapy Products in Pipeline for Dermatological Diseases
Exhibit 51 Global Cell & Gene Therapy Market by Dermatology: Incremental & Absolute Growth
Exhibit 52 Global Cell & Gene Therapy Market by Dermatology Disorders 2021-2027 ($ million)
Exhibit 53 CGT Solutions for Musculoskeletal Diseases 2019-2021 (H1)
Exhibit 54 Global Cell & Gene Therapy Market by Musculoskeletal Disorders: Incremental & Absolute Growth
Exhibit 55 Global Cell & Gene Therapy Market by Musculoskeletal Diseases 2021-2027 ($ million)
Exhibit 56 Pipeline Products in Cell & Gene Therapy for Other Diseases (2020)
Exhibit 57 Global Cell & Gene Therapy Market by Other Diseases: Incremental & Absolute Growth
Exhibit 58 Global Cell & Gene Therapy Market by Other Diseases 2021-2027 ($ million)
Exhibit 59 Incremental Growth by End-User 2021 & 2027
Exhibit 60 Criteria for Identifying Clinical Trial Sites & Treatment Centers
Exhibit 61 Global Cell & Gene Therapy Market by End-Users: Incremental Growth
Exhibit 62 Global Cell & Gene Therapy Market by End-Users: Absolute Growth
Exhibit 63 Global Cell & Gene Therapy Market by Hospitals: Incremental & Absolute Growth
Exhibit 64 Global Cell & Gene Therapy Market by Hospitals 2021-2027 ($ million)
Exhibit 65 Global Cell & Gene Therapy Market by Cancer Care Centers: Incremental & Absolute Growth
Exhibit 66 Global Cell & Gene Therapy Market by Cancer Care Centers 2021-2027 ($ million)
Exhibit 67 Global Cell & Gene Therapy Market by Wound Care Centers: Incremental & Absolute Growth
Exhibit 68 Global Cell & Gene Therapy Market by Wound Care Centers 2021-2027 ($ million)
Exhibit 69 Global Cell & Gene Therapy Market by Other End-Users: Incremental & Absolute Growth
Exhibit 70 Global Cell & Gene Therapy Market by Other End-Users 2021-2027 ($ million)
Exhibit 71 Incremental Growth by Geography 2021 & 2027
Exhibit 72 Global Cell & Gene Therapy Market by Geography: Incremental Growth
Exhibit 73 Global Cell & Gene Therapy Market by Geography: Absolute Growth
Exhibit 74 North America Regenerative Medicine Manufacturers 2017-2021
Exhibit 75 North America Cell & Gene Therapy Market: Key Countries 2021 ($ million)
Exhibit 76 North America Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 77 Incremental Growth in North America 2021 & 2027 ($ million)
Exhibit 78 US Cell & Gene Therapy Clinical Trials
Exhibit 79 Gene Therapies in US Sponsored by Authorities & Institutes 2020 (%)
Exhibit 80 US Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 81 Cell & Gene Therapy Products Approved in Canada 2017-2021
Exhibit 82 Canada Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 83 Cell & Gene Therapies in Clinical Trials in Europe 2019
Exhibit 84 Europe Cell & Gene Therapy Market: Key Countries 2021 ($ million)
Exhibit 85 Europe Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 86 Incremental Growth in Europe 2021 & 2027 ($ million)
Exhibit 87 Germany Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 88 France Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 89 UK Cell & Gene Therapy Clinical Trial by Therapeutic Areas 2021
Exhibit 90 UK Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 91 ATMP Clinical Trials in Spain (Including Cell & Gene Therapy) 2013-2018
Exhibit 92 Spain Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 93 Cell & Gene Therapy Approved Products in Italy
Exhibit 94 Italy Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 95 Growth of Regenerative Medicine Companies in APAC 2017-2020
Exhibit 96 APAC Cell & Gene Therapy Market: Key Countries 2021 ($ million)
Exhibit 97 APAC Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 98 Incremental Growth in APAC 2021 & 2027
Exhibit 99 PMDA & INDs Consultation for Cell & Gene Therapy Products 2020
Exhibit 100 Japan Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 101 China Cell & Gene Therapy Clinical Trials 2014-2019
Exhibit 102 China Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 103 Cell & Gene Therapy Clinical Trials in South Korea 2021
Exhibit 104 South Korea Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 105 Australia Cell & Gene Therapy Clinical Trials 2015-2021
Exhibit 106 Australia Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 107 India Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 108 Latin America Cell & Gene Therapy Market: Key Countries 2021 ($ million)
Exhibit 109 Latin America Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 110 Incremental Growth in Latin America 2021 & 2027
Exhibit 111 Development in Brazil for Cell & Gene Therapy Market
Exhibit 112 Brazil Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 113 Mexico Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 114 Middle East & Africa Cell & Gene Therapy Market: Key Countries 2021 ($ million)
Exhibit 115 Middle East & Africa Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 116 Incremental Growth in Middle East & Africa 2021 & 2027
Exhibit 117 Turkey Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 118 Saudi Arabia Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 119 UAE Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 120 South Africa Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 121 Israel Cell & Gene Therapy Market 2021-2027 ($ million)
Exhibit 122 Global Cell & Gene Therapy Market: Vendors Ranking 2021
Exhibit 123 Global Gene Therapy Market: Vendors Ranking 2021
Exhibit 124 Global Cell Therapy Market: Vendors Ranking 2021
Exhibit 125 Gilead Sciences: Total Revenue 2018-2020 ($ billion)
Exhibit 126 Novartis: Total Revenue 2018-2020 ($ million)
Exhibit 127 Smith Nephew: Total Revenue 2018-2020 ($ billion)
Exhibit 128 Amgen: Total Revenue 2018-2020 ($ billion)
Exhibit 129 Organogenesis: Total Revenue 2018-2020 ($ million)
Exhibit 130 Roche: Total Revenue 2018-2020 ($ billion)
Exhibit 131 Vericel: Total Revenue 2018-2020 ($ million)
Exhibit 132 Bristol Meyer Squibb: Total Revenue 2018-2020 ($ billion)
LIST OF TABLES
Table 1 Key Caveats
Table 2 Currency Conversion 2015-2021
Table 3 Cell & Gene Therapy Products Approved in 2020-2021
Table 4 Cell & Gene Therapy Products in Phase-III 2021
Table 5 Mergers & Acquisitions for Cell & Gene Therapy 2019-2021
Table 6 Expansion of Manufacturing Plants for Cell & Gene Therapy 2021
Table 7 Cell & Gene Therapy Products with Expanding Applications
Table 8 CAR T-Cell Investigational Products
Table 9 Cell & Gene Therapy Approved Products 2017-2021
Table 10 Cell & Gene Therapy Prime Designation Approved Products 2017-2021
Table 11 Cell & Gene Therapy Approved Products for Various Diseases
Table 12 Prices of Gene Therapies Marketed in Europe
Table 13 Approved Cell Therapy Products
Table 14 Cell & Gene Therapy Products for Genetic Disorders
Table 15 Global Cell & Gene Therapy Market by Geography 2021-2027 ($ million)
Table 16 Global Cell & Gene Therapy Market by Geography 2021-2027 (%)
Table 17 Approved Cell & Gene Therapy Products in Europe
Table 18 Approved Gene Therapy Products in Japan
Table 19 Development of Gene Therapies in China 2017
Table 20 Financing for Cell & Gene Therapy in Australia
Table 21 Cell & Gene Therapy Approved Products in Australia
Table 22 Gilead Sciences: Major Product Offerings
Table 23 Novartis: Major Product Offerings
Table 24 Osiris Therapeutic Inc. (Smith & Nephew): Major Product Offerings
Table 25 Amgen: Major Product Offerings
Table 26 Organogenesis: Major Product Offerings
Table 27 Roche: Major Product Offerings
Table 28 Dendreon (Sanpower Group): Major Product Offerings
Table 29 Vericel: Major Product Offerings
Table 30 Bristol Meyer Squibb: Major Product Offerings
Table 31 Abeona Therapeutics: Major Product Offerings
Table 32 APAC Biotech Pvt Ltd: Major Product Offerings
Table 33 Alnylam: Major Product Offerings
Table 34 Allovir: Major Product Offerings
Table 35 Tego Sciences: Major Product Offerings
Table 36 Avita Medical: Major Product Offerings
Table 37 Anterogen: Major Product Offerings
Table 38 ANGES Inc.: Major Product Offerings
Table 39 Biosolution Co. Ltd: Major Product Offerings
Table 40 Chiesi Farmaceutici.: Major Product Offerings
Table 41 Collplant: Major Product Offerings
Table 42 CO.DON: Major Product Offerings
Table 43 CORESTEM: Major Product Offerings
Table 44 Bluebird Bio Inc: Major Product Offerings
Table 45 Stempeutics Research: Major Product Offerings
Table 46 GC Cell: Major Product Offerings
Table 47 Sanofi Genzyme: Major Product Offerings
Table 48 Gensight biologics: Major Product Offerings
Table 49 Human Stem Cells Institute: Major Product Offerings
Table 50 JW Creagene: Major Product Offerings
Table 51 JCR Pharmaceuticals: Major Product Offerings
Table 52 JAPAN TISSUE ENGINEERING (J-TEC): Major Product Offerings
Table 53 Kolon TissueGene: Major Product Offerings
Table 54 Medipost: Major Product Offerings
Table 55 MOLMED: Major Product Offerings
Table 56 NUVASIVE Inc.: Major Product Offerings
Table 57 NIPRO Corporation: Major Product Offerings
Table 58 Orchard Therapeutics: Major Product Offerings
Table 59 Orthocell: Major Product Offerings
Table 60 Pfizer Major Product Offerings
Table 61 Pharmicell: Major Product Offerings
Table 62 Sibiono Genetech: Major Product Offerings
Table 63 Shanghai Sunway Biotech: Major Product Offerings
Table 64 RMS Regenerative Medical System: Major Product Offerings
Table 65 Takeda Pharmaceutical Company: Major Product Offerings
Table 66 Terumo: Major Product Offerings
Table 67 Biomarin Pharmaceuticals: Major Product Offerings
Table 68 Bellicum Pharmaceuticals: Major Product Offerings
Table 69 Castle Creek Biosciences Inc: Major Product Offerings
Table 70 Libella Gene Therapeutics: Major Product Offerings
Table 71 CARSGEN Therapeutics: Major Product Offerings
Table 72 Hrain Biotechnology: Major Product Offerings
Table 73 Helixmith: Major Product Offerings
Table 74 Krystal Biotech Inc.: Major Product Offerings
Table 75 JW Therapeutics: Major Product Offerings
Table 76 Poseida Therapeutics: Major Product Offerings
Table 77 Global Cell & Gene Therapy Market by Geography 2021-2027 ($ million)
Table 78 Global Cell & Gene Therapy Market by Geography 2021-2027 (%)
Table 79 Global Cell & Gene Therapy Market by Therapy Type 2021-2027 ($ million)
Table 80 Global Cell & Gene Therapy Market by Therapy Type 2021-2027 (%)
Table 81 Global Cell & Gene Therapy Market by Diseases 2021-2027 ($ million)
Table 82 Global Cell & Gene Therapy Market by Diseases 2021-2027 ($ million)
Table 83 Global Cell & Gene Therapy Market by End-User 2021-2027 ($ million)
Table 84 Global Cell & Gene Therapy Market by End User 2021-2027 (%)

Companies Mentioned

  • Gilead sciences
  • Novartis
  • Smith Nephew (Osiris Therapeutic)
  • Amgen
  • Organogenesis
  • Roche (Spark Therapeutics)
  • Dendreon
  • Vericel
  • Bristol-Myers Squibb
  • Abeona Therapeutics
  • APAC Biotech Pvt Ltd
  • Alnylam
  • Allovir
  • Tego Sciences
  • Avita Medical
  • Anterogen
  • AnGes Inc.
  • BioSolution Co. Ltd.
  • Cheisi Farmaceutici
  • CollPlant
  • CO.DON
  • Corestem
  • Bluebird Bio Inc
  • Biosolution
  • Stempeutics Research
  • GC Cell
  • Sanofi
  • Gensight biologics
  • Human Stem Cells Institute
  • JW CreaGene Co. Ltd
  • JCR Pharmaceuticals
  • Japan Tissue Engineering (J-TEC)
  • Kolon TissueGene
  • Medipost
  • MolMed
  • Nuvasive Inc.
  • Nipro Corporation
  • Orchard Therapeutics
  • Orthocell
  • Pfizer
  • Pharmicell
  • Sibiono Genetech
  • Shanghai Sunway Biotech
  • RMS Regenerative Medical System
  • Takeda Pharmaceuticals Company
  • Terumo
  • Biomarin Pharmaceutical
  • Bellicum Pharmaceutical
  • Castle Creek Biosciences Inc
  • Libella Gene Therapeutics
  • CARsgen Therapeutics
  • Hrain Biotechnology Co. Ltd
  • Helixmith
  • Krystal Biotech Inc.
  • JW Therapeutic
  • Poseida Therapeutics

Methodology


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...